Zynerba Pharmaceuticals Inc expected to post a loss of 23  cents a share - Earnings Preview

Zynerba Pharmaceuticals

06/05/2022 18:02

* Zynerba Pharmaceuticals Inc  ZYNE.OQ   ZYNE.O  is expected
to show no change in quarterly revenue when it reports 
results on May 10 (estimated). 
    * ​Refinitiv's mean analyst estimate for Zynerba
Pharmaceuticals
Inc is for a loss of 23 cents per share. For the same quarter
last year, the company reported a loss of 20 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Zynerba
Pharmaceuticals Inc is $8​, above​ its last closing price
of $1.34. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.26       -0.26      -0.22     Beat    16.5
 Sep. 30 2021  -0.25       -0.25      -0.26     Missed  -3.2
 Jun. 30 2021  -0.20       -0.24      -0.25     Missed  -5​
 Mar. 31 2021  -0.25       -0.25      -0.20     Beat    19.8
 ​​Dec.        -0.29       -0.33      -0.33     Met     -0.4
 31 2020                                                
 Sep. 30 2020  -0.43       -0.43      -0.31     Beat    28.3​
 Jun. 30 2020  -0.45       -0.45      -0.78     Missed  -74.4
 Mar. 31 2020  -0.49       -0.50      -0.53     Missed  -6.6
 This summary was machine generated May 6 at 17:02 GMT.  All
figures in US dollars  unless otherwise stated